Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100310 | 0.97 | USP2 (0.47) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL7116256 | 0.90 | USP2 (0.45) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL7545745 | 0.88 | USP2 (0.44) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL11913782 | 0.86 | USP2 (0.42) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL2139326 | 0.86 | USP2 (0.47) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL1783854 | 0.86 | USP2 (0.47) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL1638881 | 0.86 | LMNA (0.53) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL30754 | 0.86 | LMNA (0.53) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL9407351 | 0.84 | THRB (0.54) | USP2LMNAALDH1A1THRBKDM4E | |
| SCHEMBL9418186 | 0.84 | THRB (0.60) | USP2LMNAALDH1A1THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865944-B2 | Process for the purification of polyol PFPE derivatives | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2014-10-21 | — | — | US | disclosed |
| US-8664353-B2 | Process for the purification of polyol PFPE derivatives | SOLVAY SOLEXIS S.P.A. (IT) | 2014-03-04 | — | — | US | disclosed |
| US-20120055779-A1 | Process for the purification of polyol PFPE derivatives | SOLVAY SOLEXIS S.P.A. (IT) | 2012-03-08 | — | — | US | disclosed |
| US-20120059144-A1 | Process for the purification of polyol PFPE derivatives | SOLVAY SOLEXIS S.P.A. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059144-A1 | Process for the purification of polyol PFPE derivatives | PHYKPL, PKLR, PHOSPHO1 | USP2 440/4885LMNA 2429/4885ALDH1A1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.